Dastoli Stefano, Iannone Luigi Francesco, Bennardo Luigi, Silvestri Martina, Palleria Caterina, Nisticò Steven Paul, De Sarro Giovambattista, Russo Emilio
Department of Health Sciences, Unit of Dermatology, Magna Graecia University, Catanzaro, Italy.
Department of Health Sciences, Unit of Pharmacology, Magna Graecia University, Catanzaro, Italy.
Curr Drug Saf. 2020;15(1):69-72. doi: 10.2174/1574886314666190726155147.
Psoriasis is a cutaneous inflammatory condition characterized by an altered turnover of keratinocytes leading to scaly patches. Secukinumab and ixekizumab are two biologic drugs inhibiting interleukin-17.
We report the first case, according to Naranjo score, of a secukinumab-induced erectile dysfunction with severe plaque psoriasis that disappeared after switching to another anti IL17 drug (ixekizumab).
A 45 years old man experienced erectile dysfunction during treatment with an anti-IL17. The adverse effect appeared after 60 days of treatment with secukinumab and rapidly disappeared after discontinuation of the drug. All necessary urologic exams were carried out. Re-administration of secukinumab, due to the exacerbation of psoriasis, caused the same sexual dysfunction after 60 days.
Switching to ixekizumab lead to a resolution of the erectile dysfunction and a complete skin clearance.
We describe for the first time a sexual dysfunction possibly due to secukinumab and its resolution after the switch to another similar but different drug, highlighting the potential difference between anti-IL17A drugs.
银屑病是一种皮肤炎症性疾病，其特征是角质形成细胞周转改变，导致鳞屑斑块。司库奇尤单抗和依奇珠单抗是两种抑制白细胞介素-17的生物药物。
根据纳伦霍评分，我们报告首例司库奇尤单抗诱导的勃起功能障碍合并重度斑块状银屑病的病例，在换用另一种抗白细胞介素-17药物（依奇珠单抗）后，银屑病消失。
一名45岁男性在接受抗白细胞介素-17治疗期间出现勃起功能障碍。该不良反应在司库奇尤单抗治疗60天后出现，停药后迅速消失。进行了所有必要的泌尿外科检查。由于银屑病加重，再次使用司库奇尤单抗，60天后再次出现相同的性功能障碍。
换用依奇珠单抗后，勃起功能障碍得到解决，皮肤完全清除。
我们首次描述了一种可能由司库奇尤单抗引起的性功能障碍，以及换用另一种相似但不同的药物后该障碍的解决，突出了抗白细胞介素-17A药物之间的潜在差异。
